DevvStream

BELITE BIO (NASDAQ: BLTE) STOCK QUOTE

Last Trade: US$38.37 -1.56 -3.91
Volume: 35,119
5-Day Change: -13.01%
YTD Change: -16.13%
Market Cap: US$1.140B

LATEST NEWS FROM BELITE BIO

Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration (Dry AMD) Data from a 24-month Phase 2 trial in adolescent STGD1 subjects showed a sustained lower atrophic lesion growth in Tinlarebant-treated subjects compared to ProgStar participants possessing similar... Read More
SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its annual report on Form 20-F, containing audited consolidated financial statements for the year ended December 31, 2023, as filed with the... Read More
Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration (Dry AMD) Data from a 24-month Phase 2 trial in adolescent STGD1 subjects showed a sustained lower atrophic lesion growth in Tinlarebant-treated subjects compared to ProgStar participants possessing similar... Read More
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Tuesday, March 12, 2024, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business... Read More
SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in the Leerink Partners Global Biopharma Conference being held in Miami, FL, on March 11-13, 2024.... Read More
SAN DIEGO, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate at the upcoming Oppenheimer 34 th Annual Healthcare Life Sciences Conference on February 13-14 and... Read More
SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will be participating at the Benchmark Company’s 12 th Annual Discovery One-on-One Investor Conference to be held Thursday, December 7, 2023, at... Read More
SAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that management will participate in a fireside chat at the BTIG Ophthalmology Day on Monday, November 27, 2023, at 3:00 p.m. ET. The Belite management... Read More
GreenStockNews
Completed enrollment in pivotal Phase 3 “DRAGON” trial for Tinlarebant in adolescent Stargardt disease (“STGD1”) with 104 subjects enrolled across 11 countries worldwide First subject dosed with Tinlarebant in pivotal global Phase 3 “PHOENIX” trial in Geographic Atrophy (“GA”) Oral, once-daily Tinlarebant continues to be safe... Read More
SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Tuesday, November 14, 2023, at 4:30 p.m. Eastern Time to discuss the Company’s financial results for the third quarter... Read More
GreenStockNews
Tinlarebant (a/k/a LBS-008) is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration (Dry AMD) Tinlarebant was safe and well-tolerated in all subjects throughout the 24-month... Read More
Two-year data from the two-year Phase 1b/2 trial of Tinlarebant (LBS-008) in adolescent Stargardt Disease (STGD1) to be presented A two-year global Phase 3 trial in adolescent STGD1 (the “DRAGON” study) and a two-year global Phase 3 trial in Geographic Atrophy (GA) patients (the “PHOENIX” study) are on-going Tinlarebant has been granted Fast Track and Rare Pediatric Disease Designations in the U.S. and Orphan Drug... Read More
GreenStockNews
Completed enrollment in pivotal Phase 3 “DRAGON” trial for Tinlarebant in adolescent Stargardt disease (“STGD1”) with 100 subjects enrolled across 11 countries worldwide First subject dosed with Tinlarebant in pivotal global Phase 3 “PHOENIX” trial in Geographic Atrophy (“GA”) Oral, once-daily Tinlarebant continues to be safe... Read More
SAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases which have significant unmet medical needs, today announced that it will host a live webcast on Wednesday, August 9, 2023, at 4:30 p.m. Eastern Time to discuss the Company’s... Read More
Tinlarebant (a/k/a LBS-008) is Belite Bio’s orally administered tablet intended to slow disease progression in subjects with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration (Dry AMD) There are no approved oral or non-invasive treatments for GA Enrollment of approximately 430 GA subjects across multiple centers globally SAN DIEGO, July 27, 2023 (GLOBE NEWSWIRE) -- Belite... Read More
Tinlarebant (a/k/a LBS-008) is Belite Bio’s orally administered tablet intended to slow disease progression in patients with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration (Dry AMD) 90 patients completed enrollment across 11 countries worldwide Interim safety and efficacy data from the Phase 3 “DRAGON” trial for STGD1 is expected in mid-2024 Tinlarebant has been granted... Read More
SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases which have significant unmet medical needs, today announced that it has priced an underwritten public offering of 2,000,000 American Depositary Shares (“ADSs”), each... Read More
SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases which have significant unmet medical needs, today announced that it has commenced an underwritten public offering of American Depositary Shares (“ADSs”), each representing one... Read More
GreenStockNews
In 18-month interim data from ongoing 2-year, Phase 2 Stargardt disease (“STGD1”) trial (“LBS-008-CT02”), we continued to observe that oral Tinlarebant is safe and well tolerated in adolescent STGD1 subjects A continued trend of slowing expansion of autofluorescence was observed and the growth rate of incident atrophic retinal... Read More
SAN DIEGO, May 10, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases which have significant unmet medical needs, today announced it will host a live webcast on Thursday, May 11, 2023, at 8:00 a.m. Eastern Time to discuss the Company’s financial results for the first quarter... Read More
The webinar will take place on Wednesday, May 10, 2023 at 1:00 PM ET SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE), a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases which have significant unmet medical needs, today announced it will host a virtual Key Opinion Leader event on focusing on adolescent... Read More
Tinlarebant (aka LBS-008) continues to be safe and well tolerated in adolescent Stargardt Disease (STGD1) subjects at the 18-month time point A continued trend of slowing expansion of autofluorescence was observed The growth rate of incident atrophic retinal lesions was reduced compared to a natural history study of the disease (“ProgStar”) Visual acuity was stabilized with no significant loss, and no clinically significant... Read More
Virtual event on Wednesday, May 3 rd at 1:00 PM ET will feature key opinion leader Hendrik Scholl, M.D. from the University of Basel, Switzerland 18-month interim efficacy and safety data from Belite Bio’s Phase 2 trial evaluating tinlarebant in Stargardt disease 1 will be discussed SAN DIEGO, April 11, 2023 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug... Read More
12-month interim data from the ongoing 2-year, Phase 2 Stargardt disease (STGD1) study continues to show halting or slowing of lesion growth; 18-month efficacy and safety update expected during the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting on April 25 42 subjects have been enrolled for the pivotal Phase 3 “DRAGON” trial evaluating oral tinlarebant in adolescent STGD1; at least 90... Read More
SAN DIEGO, March 31, 2023 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting eye diseases with significant unmet medical needs, will host a live webcast on Monday, April 3, 2023, at 4:30 p.m. Eastern time to discuss the Company’s financial results for the full year ended December 31, 2022, and provide a general business update. The... Read More
Tinlarebant (a/k/a LBS-008) is Belite Bio’s orally administered tablet intended as an early intervention to slow disease progression in patients affected with Stargardt Disease (STGD1) and Dry Age-related Macular Degeneration (Dry AMD) There are currently no approved treatments for STGD1 and Dry AMD Currently, a 2-year Phase 2 study in adolescent STGD1 patients is ongoing and a global Phase 3 study in adolescent STGD1... Read More
“Potential Early Intervention with an Oral Treatment for Stargardt Disease and Dry Age-Related Macular Degeneration” Thursday, October 27 th at 11 AM ET Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting currently untreatable eye diseases, will host a key opinion leader (KOL) event with a focus on LBS-008 (aka Tinlarebant), the Company’s lead asset for the... Read More
LBS-008 (aka Tinlarebant) was safe and well tolerated in adolescent Stargardt Disease (STGD1) subjects at 12-month time point The majority of the subjects showed stabilization of BCVA in at least one eye A trend for preventing or slowing expansion of autofluorescence continue to be observed No atrophic lesion (DDAF) in 12 of 13 subjects at the 12-month treatment period 12-month interim data from the ongoing Phase 2 study... Read More
1-year interim data from the 2-year Phase 1b/2 trial of LBS-008 in adolescent STGD1 to be presented Belite Bio , Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting currently untreatable eye diseases, today announced that the 1-year interim data from the 2-year Phase 1b/2 trial of LBS-008 in adolescent STGD1 will be presented at the “Late Breaking Development” session at... Read More
LBS-008 (aka Tinlarebant) is Belite Bio’s orally administered tablet for early intervention to maintain the health of retinal tissue in Stargardt disease (STGD1) and Dry AMD patients A 2-year Phase 2 trial in adolescent STGD1 and a global Phase 3 trial in adolescent STGD1 are ongoing The Phase 3 trial named “DRAGON” is a Multi-center, Randomized, Double Masked, Placebo Controlled Study to Evaluate the Safety and Efficacy of... Read More
LBS-008 (aka Tinlarebant) is Belite Bio’s orally administered tablet for the treatment of Stargardt disease (STGD1) and Dry AMD A 2-year Phase 2 trial in adolescent STGD1 and a global Phase 3 trial in adolescent STGD1 are ongoing The Phase 3, Multi-center, Randomized, Double Masked, Placebo Controlled Study to Evaluate the Safety and Efficacy of TinlaRebant in the Treatment of StArGardt Disease in AdOlesceNt Subjects... Read More
- LBS-008 (aka Tinlarebant) is Belite Bio’s orally administered tablet for the treatment of Stargardt disease (STGD1) and Dry AMD - A 2-year Phase 2 trial in adolescent STGD1 and a global Phase 3 trial in adolescent STGD1 are ongoing - The Phase 3, Multicenter, Randomized, D ouble Masked, Placebo Controlled Study to Evaluate the Safety and Efficacy of Tinla R ebant in the Treatment of St A r G ardt Disease in Ad O lesce N t... Read More
Belite Bio , Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting untreatable eye diseases, will host a conference call on Thursday, August 11, 2022, at 4:30 p.m. Eastern time to discuss the Company’s financial results for the first half, ended June 30, 2022, and provide a corporate progress update. The financial results will be issued in a press release on Wednesday,... Read More
LBS-008 (a/k/a Tinlarebant) is the Company’s orally administered tablet for the treatment of Stargardt disease (STGD1) There are currently no approved treatments for STGD1 Approximately 30,000 patients in the U.S. suffer from STGD1 A 2-year Phase 2 trial in adolescent STGD1 and a global Phase 3 trial in adolescent STGD1 are ongoing The Phase 3, Multicenter, Randomized, Double Masked, Placebo Controlled Study to Evaluate the... Read More
Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical stage biopharmaceutical drug development company targeting currently untreatable eye diseases such as dry AMD and Stargardt disease, and metabolic diseases, today announced that the underwriters of its previously announced initial public offering (the “IPO”) have exercised in part their over-allotment option to purchase an additional 772,091 American... Read More
LBS-008 (aka Tinlarebant) showed an acceptable safety profile in adolescent Stargardt disease (STGD1) subjects A trend for stabilized or improved visual acuity was observed Observed adverse events were anticipated based on the mechanism of LBS-008 action STGD1 subjects from the Phase 1b study are now participating in the 2-year, Phase 2 extension Belite Bio , Inc (the “Company”) (Nasdaq: BLTE), a San Diego based clinical... Read More
Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical stage biopharmaceutical drug development company targeting currently untreatable eye diseases such as dry AMD and Stargardt disease, and metabolic diseases, today announced the closing of its previously announced initial public offering of 6 million American Depositary Shares (ADSs) at a public offering price per ADS of $6.00. Each ADS represents one... Read More

COPYRIGHT ©2022 GREEN STOCK NEWS